Abstract: A processing system for processing slaughtered and defeathered poultry bodies, comprising a plurality of processing devices which, for the processing-transport of the poultry bodies separately from a main conveyor device, is designed with a processing-holding means which is movable on a circular path. The processing system has transfer stations arranged in succession along a main conveyor line, in which the poultry bodies are transported in a suspended manner by carrier devices. Each processing device is assigned a transfer station which is formed by a transfer pair having two rotary transfer devices. The first rotary transfer device removes the poultry bodies from the carrier devices and transfers them to the processing-holding means of the processing device. The second rotary transfer device removes the processed poultry bodies from the processing-holding means of the processing device and transfers them to the carrier devices.

Abstract: The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus.

Abstract: The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, Formulas (I), (II), (III) and (IV) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent proliferative disorders and their use to manufacture a medicine to treat or prevent proliferative disorders, particularly cancer such as leukemia. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent proliferative disorders. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of proliferative disorders and pathologic conditions such as, but not limited to, cancer such as leukemia.

Abstract: Compounds that bind to phosphatidylinositol-4-kinase III? (PI4KIII?) and inhibit the binding of PI4KIII? to its substrate and/or inhibit PI4KIII? activity may be used in the treatment and/or prevention of an autoimmune or inflammatory disorder, or organ or cell transplant rejection. A new assay for identifying compounds for use in treating and/or preventing those pathological conditions, which comprises measuring the inhibition of PI4KIII? activity, is also disclosed.

Abstract: The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HN2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections.

Abstract: A processing system for processing slaughtered and defeathered poultry bodies, comprising a plurality of processing devices which, for the processing-transport of the poultry bodies separately from a main conveyor device, is designed with a processing-holding means which is movable on a circular path. The processing system has transfer stations arranged in succession along a main conveyor line, in which the poultry bodies are transported in a suspended manner by carrier devices. Each processing device is assigned a transfer station which is formed by a transfer pair having two rotary transfer devices. The first rotary transfer device removes the poultry bodies from the carrier devices and transfers them to the processing-holding means of the processing device. The second rotary transfer device removes the processed poultry bodies from the processing-holding means of the processing device and transfers them to the carrier devices.

Abstract: A series of monocyclic or bicyclic diamine-substituted thieno[2,3-d]pyrimidine and isothiazolo[5,4-d]pyrimidine derivatives are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.

Abstract: The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus.

Abstract: A series of monocyclic or bicyclic diamine-substituted thieno[2,3-d]pyrimidine and isothiazolo[5,4-d]pyrimidine derivatives are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.

Abstract: Compounds that bind to phosphatidylinositol-4-kinase III? (PI4KIII?) and inhibit the binding of PI4KIII? to its substrate and/or inhibit PI4KIII? activity may be used in the treatment and/or prevention of an autoimmune or inflammatory disorder, or organ or cell transplant rejection. A new assay for identifying compounds for use in treating and/or preventing those pathological conditions, which comprises measuring the inhibition of PI4KIII? activity, is also disclosed.

Abstract: The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, Formulas (I), (II), (III) and (IV) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent proliferative disorders and their use to manufacture a medicine to treat or prevent proliferative disorders, particularly cancer such as leukemia. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent proliferative disorders. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of proliferative disorders and pathologic conditions such as, but not limited to, cancer such as leukemia.

Abstract: The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus.

Abstract: The present invention relates to a Remote management method and related devices for use in a home network (HN) comprising a plurality of devices and a routing gateway. The Routing Gateway is coupled to each device of said plurality of devices. The Remote management method comprises the step of an Auto-Configuration Server managing either one of a dedicated device of said plurality of devices and the Routing Gateway or both at request. A further Auto-Configuration Server requesting the Auto-Configuration Server to access and configure the Routing Gateway for providing the further Auto-Configuration Server access to the Routing Gateway and subsequently the Auto-Configuration Server configuring the Routing Gateway to provide the further Auto-Configuration Server access to the Routing Gateway.

Abstract: The present invention relates to the ability to set up connections on demand between subscribers and service providers and allows network capacity to be best shared among users. Whenever a service terminal (ST) requests a service (S) from a service provider (SP), an authentication server (AUTH) checks whether the service terminal can access the requested service. If so, a network controller (CTRL) set up a connection (C) to deliver the requested service with the required quality of service, said connection being established between the network termination (NT), to which the service terminal is coupled, and the access server (AS), to which the service provider is coupled. The authentication server supplies transport requirements of the requested service for establishing the connection.

Abstract: A method of enhancing the functionality and usability of a computing device includes the step of defining a plurality of functional profiles, each functional profile having a layout appearance and one or more indicators associated with applications. The functional profiles are then stored, and one of the functional profiles is activated using a functional profile selector or triggered by external communications to a personal digital assistant, e.g. SMS. Thereafter, an application is activated by selecting one of the indicators from those displayed in the layout appearance for the activated functional profile.

Abstract: Tumor rejection antigens presented by HLA-B44 molecules are described. These peptides are useful in diagnostic and therapeutic methodologies. The tumor rejection antigens are not derived from tyrosinase, which has previously been identified as a tumor rejection antigen precursor processed to an antigen presented by HLA-B44.

Abstract: Tumor rejection antigens presented by HLA-244 molecules are described. These peptides are useful in diagnostic and therapeutic methodologies. The tumor rejection antigens are derived from MAGE tumor rejection antigen precursors.

Abstract: A cut is made in the neck of slaughtered poultry to permit access to a tool for removing the crop. The cut is made by an apparatus which includes a carousel for moving the poultry, arch-shaped tracks which have sections which are horizontal, upward-sloping and downward-sloping, and running wheels which move in the tracks to effect vertical movement of handling units and bird positioning units. Each handling unit includes a tilting arm which has a blade fitted at its upper end, a centering fork with two centering elements which contact opposite sides of the neck of a bird, and a running wheel at its lower end where the running wheel rides in a track. During movement of the running wheel on its track, the tilting arm is first tilted from its sloping non-operative position to a less sloping vertical position to center the neck of a bird and to bring the blade against the neckskin, and the arm then makes a downward movement to form a cut in the neck.

Abstract: Tumor rejection antigens presented by HLA-B44 molecules are described. These peptides are useful in diagnostic and therapeutic methodologies. The tumor rejection antigens are not derived from tyrosinase, which has previously been identified as a tumor rejection antigen precursor processed to an antigen presented by HLA-B44.

Abstract: Tumor rejection antigens presented by HLA-B44 molecules are described. These peptides are useful in diagnostic and therapeutic methodologies. The tumor rejection antigens are derived from MAGE tumor rejection antigen precursors.